South Korean pharmaceutical giant Celltrion announced the first batch of results from its phase two COVID-19 treatment clinical trial.
Recovery time could be reduced and the chances of being severely ill decreased by 54 percent.
For moderate cases among patients aged 50 or older it's 68 percent.
Recovery time is three days faster than the placebo and for those 50 or over with moderate symptoms, it's five to six days faster.
No one died during the trial or suffered adverse reactions.
If approved, the Korean company's product will be the nation's first COVID-19 treatment.